Cardio Town Hall: ATTR Cardiac Amyloidosis

Interactive Learning, Real-Time Expertise

Cardio Town Hall Logo ATTR Cardiac Amyloidosis

About Cardio Town Hall

HFSA’s Cardio Town Hall program delivers timely, expert-led discussions on key cardiovascular topics in a convenient, interactive format. Each 30-minute live seminar features Q&A with leading clinicians, recordings, and downloadable resources available for OnDemand learning. This series is designed to support diverse learning styles and provide practical insights for clinicians specializing in heart failure care.

July 23, 2026 | 5:00 PM - 5:30 PM ET | Virtual Livestream; OnDemand to follow

Join us for the Cardio Town Hall: Expert Perspectives on Contemporary ATTR-CM Clinical Research

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease associated with significant morbidity and mortality. As the understanding of ATTR-CM continues to evolve, clinical research plays an important role in advancing knowledge of disease characteristics, patient populations, study design, and emerging approaches to care. Join HFSA’s Cardio Town Hall for an expert discussion on contemporary ATTR-CM clinical research and its relevance to clinical practice.

Faculty

Speaker: Mathew Maurer, MD
Columbia University Irving Medical Center Vivian and Seymour Milstein Family Heart Center

Speaker: Mazen Hanna, MD
Section of Heart Failure and Cardiac Transplant
Cleveland Clinic  

The content was independently developed by HFSA , the program was funded by AstraZeneca and IONIS

Target Audience

Cardiologists, interventional cardiologists, primary care physicians, cardiac surgeons, internists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers who care for patients with heart failure.

Educational Statement

The Cardio Town Hall Series is a non-accredited educational program that utilizes an online format to provide timely information and the opportunity to interact with faculty and ask questions to find more information about amyloidosis.